Agency Business briefs

Share this article:
Euro RSCG Worldwide PR launched Health Buzz Group, a global social media brand “created in response to growing client interest in big, splashy ‘wows' from small budgets in quick time frames using traditional and social media to generate momentum.” It's an outgrowth of the firm's Buzz Group, which services such brands as Ford and Durex.

Publicis Healthcare Communications Group named Jacque Fisher managing director of Maxcess Managed Markets and Medicus International New York. She joins from Parexel MMS, where she turned around revenues as VP/general manager.
Ogilvy CommonHealth spun off SCI Scientific Communications & Information as a wholly owned separate legal entity, strengthening the firewall of the medical-affairs firm, which will continue to use shared back-end services like HR, IT and finance.

Publicis Healthware International partnered with dotSUB on, a health video portal. The site's health and wellness content is accessible in any language, the companies said. Offerings will include the ability for multiple channels, 24/7 monitoring, maintenance and verified translations.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?